Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Invest Dermatol. 2018 Feb 13;138(7):1539–1545. doi: 10.1016/j.jid.2018.01.032

Figure 2. Severity of alopecia tool (SALT) scores for individual patients.

Figure 2.

(a) during treatment (solid lines) and following cessation of (dashed lines) tofacitinib treatment. An “X” corresponding to each respective patient line indicates time at which treatment was stopped. In the event of a patient dropping out of the study prior to tofacitinib discontinuation or being lost to follow up, the “X” is placed at the end of the patient line. (b) Percentage regrowth for individual patients during and following cessation of tofacitinib treatment.